# X4 Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference
Canonical URL: https://biopharmsignal.com/news/XFOR/x4-pharmaceuticals-to-present-at-the-2026-jefferies-global-healthcare-conference-7aa62ad2
Ticker: XFOR
Company: X4 Pharmaceuticals
Source: X4 Pharmaceuticals
Published: 2026-05-27 11:00 EST
## Summary

X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology...

## Article Body
X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that management will present at the 2026 Jefferies Global Healthcare Conference on Thursday, June 4, 2026 at 3:45 p.m. ET.

A link to the live and archived webcast may be accessed on X4 Pharmaceuticals’ website under the Investors section: Events and Presentations .

About X4 Pharmaceuticals

X4 Pharmaceuticals is a company focused on improving the lives of people with rare hematology diseases by developing and commercializing innovative therapies in areas with significant unmet needs. Leveraging expertise in diseases of the immune system and CXCR4 biology, X4 has successfully developed mavorixafor, an orally available CXCR4 antagonist that is approved in the U.S. and EU as XOLREMDI ® for patients with WHIM syndrome. The Company is currently conducting a global, pivotal Phase 3 clinical trial (4WARD) evaluating mavorixafor in chronic neutropenic disorders. The U.S. FDA has granted Fast Track designation to mavorixafor for the treatment of chronic neutropenia. X4 is headquartered in Boston, Massachusetts. For more information, please visit www.x4pharma.com .

X4 Investor Contact: Remy Bernarda Jenny Kobin IR Advisory Solutions ir@x4pharma.com

Source: X4 Pharmaceuticals, Inc.
## Recent Company News
- 2026-07-07 20:30 EST — [X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/XFOR/x4-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c--477fc08a) — Source: X4 Pharmaceuticals
- 2026-07-01 11:00 EST — [X4 Pharmaceuticals Appoints Kelly Gold, Experienced Chief Financial Officer, to its Board of Directors](https://biopharmsignal.com/news/XFOR/x4-pharmaceuticals-appoints-kelly-gold-experienced-chief-financial-officer-to-it-316d9f27) — Source: X4 Pharmaceuticals
- 2026-06-01 20:30 EST — [X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/XFOR/x4-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c--f8e34e98) — Source: X4 Pharmaceuticals
- 2026-05-27 11:00 EST — [X4 Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference](https://biopharmsignal.com/news/XFOR/x4-pharmaceuticals-to-present-at-the-2026-jefferies-global-healthcare-conference-7aa62ad2) — Source: X4 Pharmaceuticals
- 2026-05-06 11:15 EST — [X4 Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/XFOR/x4-pharmaceuticals-reports-first-quarter-2026-financial-results-and-provides-cor-86158817) — Source: X4 Pharmaceuticals
## Related News
- 2026-07-29 10:30 EST — BSX — [Boston Scientific announces results for second quarter 2026](https://biopharmsignal.com/news/BSX/boston-scientific-announces-results-for-second-quarter-2026-cbac35ee)
- 2026-07-28 20:15 EST — BDX — [BD Board Declares Dividend](https://biopharmsignal.com/news/BDX/bd-board-declares-dividend-ea66eb4a)
- 2026-07-28 13:00 EST — ENLV — [Enlivex Announces $400,000,000 Private Placement](https://biopharmsignal.com/news/ENLV/enlivex-announces-400-000-000-private-placement-20e71a7a)
- 2026-07-28 12:30 EST — XRAY — [Dentsply Sirona Advances Commercial Growth Strategy in Canada Through Expanded Medline Sinclair Relationship](https://biopharmsignal.com/news/XRAY/dentsply-sirona-advances-commercial-growth-strategy-in-canada-through-expanded-m-e2440bb2)
- 2026-07-28 12:30 EST — RLMD — [Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer](https://biopharmsignal.com/news/RLMD/relmada-therapeutics-appoints-uro-oncology-leader-bipin-dalmia-as-chief-business-5c4d7b11)